Key Highlights
● Vaxcyte's VAX-31 Vaccine met all prespecified primary endpoints in the pivotal OPUS-1 trial.
● The trial enrolled 4,047 adults and compared VAX-31 with Pfizer's Prevnar 20 and Merck's Capvaxive.
● Guggenheim raised its price target to $125 from $116 on the results.
Vaxcyte rocketed on Monday, Oct. 5, after its 31-strain pneumococcal vaccine met every main goal in a pivotal late-stage trial against shots from Pfizer and Merck.
A pivotal win
Vaxcyte (NASDAQ:PCVX) rocketed on the Nasdaq Composite on Monday after reporting topline results from OPUS-1, the pivotal Phase 3 trial of its adult vaccine VAX-31. Reports differed widely on how far the stock climbed during the day, but every account showed a dramatic jump.
VAX-31 is a 31-valent pneumococcal conjugate vaccine, designed to protect against 31 strains of the bacteria that cause pneumonia and other serious infections. The trial met all of its prespecified primary endpoints.
The study enrolled 4,047 adults aged 50 and older at about 30 US sites and compared VAX-31 with Pfizer's (NYSE:PFE) Prevnar 20 and Merck's (NYSE:MRK) Capvaxive. No vaccine-related serious adverse events were reported.
VAX-31 was shown to be non-inferior to Pfizer's Prevnar 20 on the strains the two vaccines share. Against Merck's Capvaxive, it missed a stricter statistical bound on two serotypes, 3 and 12F, but cleared a historical benchmark on both.
The company also reported superiority on strains that only VAX-31 covers.
CEO Grant Pickering said: "VAX-31's combination of broader coverage and robust immune responses...sets a new benchmark for the class."
Guggenheim raised its price target to $125 from $116. Analyst Seamus Fernandez said: "The adult VAX-31 OPUS-1 Phase 3 was a major win not only vs. investor expectations and delivering our Best Case scenario, but also setting up VAX-31 for clear commercial leadership."
Vaccines in focus
Vaxcyte's results turned the spotlight on vaccine stocks. Novavax (NASDAQ:NVAX) surged in a short-squeeze-style rally, helped in part by unconfirmed reports of a suspected plague case at a Russian lab. Moderna (NASDAQ:MRNA) rallied ahead of joining the Nasdaq-100 on Oct. 9.
Merck and Pfizer both fell on the day. No source explicitly tied those moves to Vaxcyte's data. Health care overall was among the weaker sectors.
Records on the Nasdaq
The broader market was strong. The Nasdaq Composite jumped 286.45 points to a record 27,477.31, and the Nasdaq-100 closed at a record 31,076.44. The S&P 500 added 51.23 points to 7,773.95, just shy of its summer record. The Dow rose 90.94 points to 51,267.90.
That came despite the 10-year Treasury Yield climbing to its highest level since 2002. Friday's weak jobs report, with payrolls up just 29,000, cut bets on an October Fed hike, while Monday's ISM services prices-paid index hit 74.0, the highest since July 2022.
The road to approval
Vaxcyte still has more work ahead. Data from two further studies, OPUS-2 and OPUS-3, are expected in 2027, and the company plans to file with the US Food and Drug Administration in the first half of 2028.
Approval is not guaranteed, and regulators will review the full data. But Monday's results cleared the biggest hurdle so far for the program.
Chief medical officer Luis Jodar said the vaccine could provide additional coverage of invasive pneumococcal disease and pneumococcal pneumonia compared with currently available adult vaccines.
Several reports showed bigger gains before the open than later in the session, suggesting some of the early jump faded.
What to watch
Investors will watch for full OPUS-1 data at a future medical meeting and for the OPUS-2 and OPUS-3 readouts in 2027. Vaxcyte's next Quarterly Report will update its cash position and plans.
On the macro calendar, minutes from the Fed's September meeting are due Wednesday, Oct. 7 at 2 p.m. ET, and the Fed meets again Oct. 27 to 28.






Please wait processing your request...